Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ (99,916)		$ (28,500)
Income from discontinued operations, net of tax	0		(183)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	10,648		7,447
Non-cash interest on convertible senior notes	4,250		0
Amortization of deferred financing costs	993		0
Losses from investments in investees	7,861		1,464
Equity-based compensation – employees and non-employees	7,411		3,281
Provision for bad debts	810		11
Provision for inventory obsolescence	1,529		1,520
Revenue from receipt of equity	(12,680)		(159)
Realized gain on sale of equity securities	(10,953)		0
Loss on conversion of 3.00% convertible senior notes	8,688		0
Loss on sale of property, plant and equipment	56		0
Change in fair value of derivatives instruments	38,691		(1,309)
Change in fair value of contingent consideration	4,173		2,665
Deferred income tax benefit	(197)		0
Changes in assets and liabilities of continuing operations, net of the effects of acquisitions:
Accounts receivable	(724)		(184)
Inventory	952		(4,443)
Prepaid expenses and other current assets	(2,081)		(1,312)
Other assets	525		77
Accounts payable	2,303		(331)
Foreign currency measurement	(1,409)		(204)
Accrued expenses	6,928		459
Cash used in operating activities of continuing operations	(32,142)		(19,701)
Cash used in operating activities of discontinued operations	0		14
Net cash used in operating activities	(32,142)		(19,687)
Cash flows from investing activities:
Investments in investees	(13,341)		(2,700)
Proceeds from sale of equity securities	11,628		0
Acquisition of businesses, net of cash	20,528		(10,512)
Purchase of marketable securities	(50,027)		(28,923)
Maturities of short-term marketable securities	25,016		10,000
Proceeds from the sale of property, plant and equipment	631		0
Capital expenditures	(2,991)		(1,064)
Net cash used in investing activities	(8,556)		(33,199)
Cash flows from financing activities:
Issuance of 3.00% convertible senior notes, net, including related parties	170,184		0
Payment of Series D dividends, including related parties	(3,015)		0
Proceeds from the exercise of Common Stock options and warrants	5,061		1,702
Borrowings on lines of credit	24,613		29,389
Repayments of lines of credit	(27,706)		(26,108)
Net cash provided by financing activities	169,137		4,983
Effect of exchange rate on cash and cash equivalents	34		(185)
Net increase (decrease) in cash and cash equivalents	128,473		(48,088)
Cash and cash equivalents at beginning of period	27,361	[1]	71,516
Cash and cash equivalents at end of period	155,834	[1]	23,428
SUPPLEMENTAL INFORMATION:
Interest paid	3,126		613
Income taxes paid, net	316		515
Revenue related to sale of intellectual property	12,500		0
Non-cash financing:
Series D Preferred Stock	24,386		0
3.00% convertible senior notes			0
Common Stock warrants, net exercised	815		7
PROLOR [Member]
Issuance of Common Stock to acquire:
Stock Issued	586,643		0
Cytochroma [Member]
Issuance of Common Stock to acquire:
Stock Issued	146,902		0
OPKO Brazil [Member]
Issuance of Common Stock to acquire:
Stock Issued	436		0
Farmadiet [Member]
Issuance of Common Stock to acquire:
Stock Issued	$ 4,404		$ 805

[1] As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.